HeraMED receives FDA clearance for HeraBEAT
Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA).
The FDA evaluates a wide range of items for medical use, including drugs and medical devices.
The pre-market review process for the HeraBEAT US device commenced in late April 2019 and included a rigorous review by FDA of HeraMED’s comprehensive testing of the HeraBEAT US device.
Receiving the 510(k) clearance for the HeraBEAT US device allows that product to be commercially distributed throughout the United States.
Given that FDA clearance will enable HeraMED to progress its entry into the US market, this represents one of the most significant milestones in what has been a memorable maiden year for the Company.
Importantly, HeraMED already has established relationships in the US, most notably with the globally recognised Mayo Clinic, its current clinical, research and development collaborator.
Key points in FDA clearance
Working through the FDA clearance, the intended focus is for HeraBEAT US to detect foetal heart beats, display foetal heart rate, and play the foetal heart sound.
Further, HeraBEAT US is indicated for use by medical professionals in clinical or home care settings for singleton pregnancies from 12 weeks gestation.
In terms of componentry, the handheld HeraBEAT US device incorporates an ultrasound transducer, rechargeable battery, and internal microcontroller and Bluetooth Low Energy (BLE) chip for wireless data transfer from the HeraBEAT US device to the user’s smartphone.
The device offers several advantages, including a portable Ultrasound Doppler device that makes it reliable, safe to use and proven, whilst amplifying its accuracy and efficiency.
The HeraBEAT US application can be downloaded from an app store to the user's smartphone.
The HeraBEAT US application is used to communicate with the HeraBEAT US device using wireless BLE.
It controls the operation of the device and receives the FHR values for numerical display to the user while also playing the FHR sound and storing the FHR values in a history log.
All of these attributes assist expecting mothers in monitoring their pregnancies in a user-friendly manner.
HeraMED is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, to deliver better care at a lower cost.
Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.
Mayo Clinic and HMD will lead the digital transformation of prenatal care
HeraMED will progress the device’s entry into the US market, as quickly as practicable.
To expedite this process, management will liaise with its current clinical and research and development collaborator the Mayo Clinic, as well as other medical institutions, hospitals and medical professionals to drive growth and product uptake.
The United States represents a potentially large and addressable market for the HeraBEAT US device, in which approximately four million pregnancies occur annually.
HeraMED is confident that the HeraMED device will be well received in that market.
Discussing the significance of this development, chief executive and co-founder Mr. David Groberman said, “Receiving FDA 510(k) clearance for the HeraBEAT US device is a tremendous achievement for HeraMED.
‘’The device development and testing which has provided substantial evidence of the safety and effectiveness of the device has passed a challenging and rigorous period of review by the FDA and it is now ready for distribution throughout the United States in the coming months.
‘’Management will liaise with its in country partners, to ensure that process is as streamlined as possible.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.